An updated patent review of Nrf2 activators (2020-present)

Expert Opin Ther Pat. 2023 Jan;33(1):29-49. doi: 10.1080/13543776.2023.2178299. Epub 2023 Feb 18.

Abstract

Introduction: The nuclear factor erythroid 2-related factor 2 (Nrf2) is a pivotal transcription factor that controls the expression of numerous cytoprotective genes and regulates cellular defense system against oxidative insults. Thus, activating the Nrf2 pathway is a promising strategy for the treatment of various chronic diseases characterized by oxidative stress.

Areas covered: This review first discusses the biological effects of Nrf2 and the regulatory mechanism of Kelch-like ECH-associated protein 1-Nrf2-antioxidant response element (Keap1-Nrf2-ARE) pathway. Then, Nrf2 activators (2020-present) are summarized based on the mechanism of action. The case studies consist of chemical structures, biological activities, structural optimization, and clinical development.

Expert opinion: Extensive efforts have been devoted to developing novel Nrf2 activators with improved potency and drug-like properties. These Nrf2 activators have exhibited beneficial effects in in vitro and in vivo models of oxidative stress-related chronic diseases. However, some specific problems, such as target selectivity and brain blood barrier (BBB) permeability, still need to be addressed in the future.

Keywords: ARE; Keap1; Nrf2 activators; chronic diseases; electrophilic activators; protein–protein interaction inhibitors.

Publication types

  • Review

MeSH terms

  • Antioxidants / pharmacology
  • Humans
  • Kelch-Like ECH-Associated Protein 1 / chemistry
  • Kelch-Like ECH-Associated Protein 1 / genetics
  • Kelch-Like ECH-Associated Protein 1 / metabolism
  • NF-E2-Related Factor 2*
  • Oxidative Stress
  • Patents as Topic*

Substances

  • NF-E2-Related Factor 2
  • Kelch-Like ECH-Associated Protein 1
  • Antioxidants